ROCKVILLE, Md.--(BUSINESS WIRE)--Trophogen, Inc. today announced that the company has completed a
licensing and purchase agreement granting Zoetis, Inc., the leading
global animal health company, an exclusive license to develop
Trophogen’s recombinant modified bovine Follicle-Stimulating Hormone
(rbFSH) analog in the field of animal health reproduction. Under the
terms of the agreement, the recombinant long-acting bovine
FSH superagonist analog will be evaluated and developed for its
potential use in superovulation and embryo transfer in beef and dairy
cows.

“We believe Trophogen’s proprietary recombinant technology will make
possible the development of uniquely differentiated FSH proteins that
will significantly impact the reproduction management of cattle and
other animals,” said Trophogen’s President and Chief Executive Officer,
Bruce Weintraub, M.D. “We are quite privileged to have Zoetis as the
development partner conducting additional clinical field trials given
the company’s deep expertise and diverse portfolio of livestock
reproductive products. We look forward to exploring the potential of
this product with them to bring innovative recombinant biologics to
animal reproduction and value to the veterinary industry.”

Terms of the agreement were not disclosed.

About Trophogen, Inc.

Trophogen, Inc. is a U.S.-based biotechnology company founded in 2001
with Series A funding from Toucan Capital, in late stage preclinical
focusing on development of human and bovine high affinity glycoprotein
hormone and related growth factor superagonist analogs which are
long-acting, more potent and efficacious, for human infertility, animal
superovulation, wound healing as well as targeted therapy and imaging of
thyroid, ovarian, breast, prostate and testicular cancers. Trophogen has
also received over $10 million from 10 NIH and FDA small business SBIR
grants to take other advanced pre-clinical human products to Phase I-II
clinical trials by 2016-2017 for additional multibillion dollar markets.
It has also received over $4 million from various human and veterinary
pharmaceutical co-development and licensing agreements. For more
information about Trophogen, please visit www.trophogen.com.